Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

September 22, 2026

EC approves Menarini and NewAmsterdam’s obicetrapib therapies

The European Commission (EC) has granted marketing authorisation to NewAmsterdam Pharma and Menarini Group for Ubeslo (obicetrapib 10mg monotherapy) and Evlarco (10mg obicetrapib plus 10mg ezetimibe fixed-dose combination).

EC approves Menarini and NewAmsterdam’s obicetrapib therapies